British journal of anaesthesia · 2008
Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G
Аннотация
BACKGROUND: Block of parietal nociceptive afferent nerves using continuous wound infiltration with local anaesthetics may be beneficial in multimodal postoperative pain management. The effectiveness of continuous wound infusion of ropivacaine for postoperative pain relief after open nephrectomy was analysed in a prospective, randomized, double-blinded, placebo-controlled trial.
METHODS: One hundred and sixty-eight patients were randomized to either 0.5% ropivacaine (ON-Q group) or 0.9% NaCl (control group), using an elastomeric pump which delivered 4 ml h(-1) over 48 h through two multiholed Soaker catheters placed between the transverse and the internal oblique muscles and the s.c. space. All patients received a standard postoperative pain management protocol, including patient-controlled analgesic morphine and ketorolac. Outcomes measured over 48 h after operation were visual analogue scale (VAS) and incident (i) VAS pain scores, morphine consumption, and side-effects; time to bowel function recovery; and mean length of hospitalization.
RESULTS: Side-effects were similar between the two groups. VAS and i-VAS pain scores, morphine consumption [11.5 (0.27) vs 21.8 (0.37) mg; P<0.001], time to bowel recovery [21.8 (0.4) vs 33.6 (0.9) h; P<0.001], and mean length of hospitalization [2.1 (0.03) vs 3.2 (0.1) days; P<0.001] were significantly reduced in the ON-Q group. Cost analysis revealed an overall savings of approximately 273 euros per patient in the ON-Q group.
CONCLUSIONS: Continuous surgical wound infusion with ropivacaine improved pain relief and accelerated recovery and discharge reducing overall costs of care.
METHODS: One hundred and sixty-eight patients were randomized to either 0.5% ropivacaine (ON-Q group) or 0.9% NaCl (control group), using an elastomeric pump which delivered 4 ml h(-1) over 48 h through two multiholed Soaker catheters placed between the transverse and the internal oblique muscles and the s.c. space. All patients received a standard postoperative pain management protocol, including patient-controlled analgesic morphine and ketorolac. Outcomes measured over 48 h after operation were visual analogue scale (VAS) and incident (i) VAS pain scores, morphine consumption, and side-effects; time to bowel function recovery; and mean length of hospitalization.
RESULTS: Side-effects were similar between the two groups. VAS and i-VAS pain scores, morphine consumption [11.5 (0.27) vs 21.8 (0.37) mg; P<0.001], time to bowel recovery [21.8 (0.4) vs 33.6 (0.9) h; P<0.001], and mean length of hospitalization [2.1 (0.03) vs 3.2 (0.1) days; P<0.001] were significantly reduced in the ON-Q group. Cost analysis revealed an overall savings of approximately 273 euros per patient in the ON-Q group.
CONCLUSIONS: Continuous surgical wound infusion with ropivacaine improved pain relief and accelerated recovery and discharge reducing overall costs of care.